Identifying a wide range of mutations in the BRAF gene for prescribing targeted drugs for melanoma treatment
https://doi.org/10.20340/vmi-rvz.2023.1.CLIN.4
Abstract
Melanoma is an aggressive malignancy of the skin and mucosa of neuroepithelial nature, heterogeneous both in phenotype and molecular genetic characteristics, with a high risk of progression and a steadily increasing incidence of about 5% a year. The development of melanoma is due to both external (UV exposure) and internal factors, the main ones being mutations in oncogenes and tumour suppressor genes. Hyperactivation of RAS/RAF/MEK/ERK signalling pathway is observed in 75% of skin melanoma cases, and one of its key factors is serine threonine kinase encoded by BRAF gene. Oncogenic mutations of BRAF mimic the phosphorylation of the activation loop of the protein, which results in BRAF being in a permanently activated state. Subsequent operation of the MAPK signalling pathway in a non-stop mode and loss of BRAF negative feedback leads to uncontrolled cell growth and proliferation. The most common mutations in the BRAF gene are p.V600E (valine replacement for glutamic acid), which accounts for up to 95% of all BRAF-mutant melanomas, and p.V600K (valine replacement for lysine), which can account for up to 20% of cases or more. Development of non-selective and selective inhibitors of mutant BRAF protein make mutation in this gene a predictive marker of response and efficacy of targeted therapy.
About the Authors
A. N. Toropovskiy
"SJI"
Russian Federation
Russian Federation
Ulyanovsk
A. G. Nikitin
TESTGEN
Russian Federation
Russian Federation
Ulyanovsk
A. V. Solov'ev
TESTGEN
Russian Federation
Russian Federation
Ulyanovsk
R. M. Khuzina
TESTGEN
Russian Federation
Russian Federation
Ulyanovsk
O. N. Pavlova
TESTGEN;
Samara State Medical University
Russian Federation
Russian Federation
Ulyanovsk;
Samara
References
1. 1 Erdmann F, Lortet-Tieulent J, Schuz J, et al. International trends in the incidence of malignant melanoma 1953–2008–are recent generations at higher or lower risk? Int J Cancer. 2013;132:385–400. https://doi.org/10.1002/ijc.2761
2. 2 Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options. Scientifica. 2013:635203.
3. 3 Thomas L., Tranchand P., Berard F. et al. Semiological value of ABCDEcriteria in the diagnosis of cutaneous pigmented tumors. Dermatology (Basel). 1998; 197: 11–17. https://doi.org/10.1159/000017969
4. 4 Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: Herzen Scientific Research Institute of Radiology, branch of NMRC of Radiology, Ministry of Health of Russia. 2020:252. (In Russ)
5. 5 Lens M.B., Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol. 2004;150:179-185
6. 6 Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B. et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363(8):711–723. https://doi.org/10.1056/NEJMoa1003466
7. 7 Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene. 2010;29(41):5545–5555.
8. 8 Davies H., Bignell G. R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–954.
9. 9 Kit O.I., Vodolazhsky D.I., Zlatnik E.Yu., Efimova I.Yu., Kochuev S.S., Przhedetsky Y.V. Association of mutation status of BRAF gene and clinical and morphological features of skin melanoma. Kuban Scientific Medical Bulletin. 2016;3. (In Russ). URL: https://cyberleninka.ru/article/n/assotsiatsiya-mutatsionnogo-statusa-gena-braf-i-klinikomorfologicheskih-osobennostey-melanomy-kozhi
10. 10 Dankner M., Lajoie M., Moldoveanu D., Nguyen T.T., Savage P., Rajkumar S. et al. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clin Cancer Res. 2018;24(24):6483–6494. https://doi.org/10.1158/1078-0432.CCR-17-3384
11. 11 Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F. et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Cancer Res. 2012;18(12):3242–3249. https://doi.org/10.1158/1078-0432.CCR-12-0052
12. 12 Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S. et al. Mutations of the BRAF Gene in Human Cancer. Nature. 2002;417(6892):949–954. https://doi.org/10.1038/nature00766
13. 13 Menzies A.M., Haydu L.E., Visintin L., Carlino M.S., Howle J.R., Thompson J.F. et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Cancer Res. 2012;18(12):3242–3249. https://doi.org/10.1158/1078-0432.CCR-12-0052
14. 14 Shi, H., Moriceau, G., Kong, X., Lee, M., Lee, H., Koya, R., Ng, C., Chodon, T., Scolyer, R.A., Dahlman, K.B., Sosman, J.A., Kefford, R.F., Long, G.V., Nelson, S.F., Ribas, A., & Lo, R.S. Melanoma whole exome sequencing identifies V600EB-RAF amplificationmediated acquired B-RAF inhibitor resistance. Nature communications. 2012;3:724–724.
15. 15 Ascierto P.A., McArthur G.A., Dréno B., Atkinson V., Liszkay G., Di Giacomo A.M. et al. Cobimetinib Combined with Vemurafenib in Advanced BRAF(V600)-Mutant Melanoma (coBRIM): Updated Efficacy Results from a Randomised, Double-Blind, Phase 3 Trial. Lancet Oncol. 2016;17(9):1248–1260. https://doi.org/10.1016/S1470-2045 (16)30122-X
16. 16 Zaretsky A.R., Demidov L.V., Samoilenko I.V. Biomarkers in metastatic skin melanoma: can we choose treatment tactics more accurately for our patients? Medical Advice. 2021;9:48–63. https://doi.org/10.21518/2079-701X-2021-9-48-63 (In Russ)]
Review
For citations:
Toropovskiy A.N., Nikitin A.G., Solov'ev A.V., Khuzina R.M., Pavlova O.N. Identifying a wide range of mutations in the BRAF gene for prescribing targeted drugs for melanoma treatment. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2023;13(1):71-76. (In Russ.) https://doi.org/10.20340/vmi-rvz.2023.1.CLIN.4
Views:
289
Email this article 